Navigation Links
FASEB announces 2014 Science Research Conference: Lipid and Lipid Regulated Kinases in Cancer
Date:1/22/2014

Bethesda, MD This 2014 FASEB Science Research Conference focuses on recent advances in our understanding of lipid-regulated signal transduction cascades, lipid mediators, and lipid targets that are known to play major roles in the initiation and progression of human cancers.

This FASEB Conference brings together physician-scientists, basic scientists and scientists from industry for presentations, discussion, and collaboration to broaden our understanding of how these pathways drive cancer, and to explore these and the associated signaling network as targets for cancer therapy. There are numerous challenges in this relatively young, yet rapidly evolving field. Perhaps most critical is understanding the molecular mechanisms by which lipid effectors modulate mitogenesis, cell cycle regulation, cell death and differentiation in transformed cells, and elucidating how intracellular generation of bioactive lipids is altered in transformed cells and contributes to cancer progression.

This meeting strives to provide researchers with an update on current basic, mechanistic discoveries, and to place these discoveries in the proper translational and clinical context. Meeting topics include: The phosphoinostide pathway and its effectors including the protein kinase C (PKC) isozymes, Rho family GTPases, and Ras; modification of membrane phosphoinostides by PI3K, activation of the Akt isozymes and their downstream targets such as mTOR; new phospholipases and the characterization of novel effectors of bioactive products such as COX2 and the isoprostanes; and lipid post-translational modifications of the Ras oncogene and other GTPases that contribute to their transforming activities.


'/>"/>

Contact: Robin Crawford
src@faseb.org
301-634-7010
Federation of American Societies for Experimental Biology
Source:Eurekalert

Page: 1

Related biology news :

1. FASEB announces 2014 Science Research Conference: Folic Acid, Vitamin B12 and One Carbon Metabolism
2. FASEB announces 2014 SRC: Phospholipid Cell Signaling & Metabolism in Inflammation & Cancer
3. FASEB announces 2014 Science Research Conference: Molecular Biophysics of Membranes
4. FASEB announces 2014 SRC: Translational Neuroimmunology: From Mechanisms to Therapeutics
5. FASEB announces 2014 Science Research Conference: Nutrient Sensing and Metabolic Signaling
6. FASEB announces 2014 Science Research Conference: Retinal Neurobiology and Visual Processing
7. FASEB announces 2014 Science Research Conference: Virus Structure and Assembly
8. FASEB announces 2014 Science Research Conference: Protein Folding in the Cell
9. FASEB announces 2014 Science Research Conference: 2nd International Conference on Retinoids
10. FASEB announces SRC: Molecular Mechanisms of Intestinal Lipid Transport & Metabolism
11. FASEB announces 2014 SRC: Protein Phosphorylation, Cellular Plasticity & Signaling Rewiring
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/20/2016)... , Dec. 20, 2016 The rising ... rental and leasing is stoking significant interest in ... frequency technology, Bluetooth low energy (BLE), biometrics and ... the next wave of wireless technologies in the ... system to advanced access systems opens the market ...
(Date:12/19/2016)... TORONTO , 19 de diciembre de 2016  Mosaic ... permitirá el desarrollo acelerado de MSC-1, un anticuerpo humanizado que se ... tumor en 2017, con múltiples sitios previstos a lo largo de ... ... el factor inhibidor de leucemia (LIF), una citoquina pleiotrópica que se ...
(Date:12/16/2016)... , Dec 16, 2016 Research and ... System Market - Global Forecast to 2021" report to their ... The ... to grow at a CAGR of 14.06% from 2016 to 2021. ... and is projected to reach 854.8 Million by 2021. The growth ...
Breaking Biology News(10 mins):
(Date:1/17/2017)... , Jan. 17, 2017  Protagonist Therapeutics, Inc. ... it has initiated a global Phase 2b induction ... peptide that targets alpha4beta7 integrin. The aim of ... to evaluate the safety/tolerability and efficacy of PTG-100 ... moderate to severe active disease. ...
(Date:1/16/2017)... , Jan. 16, 2017   Valentin A. Pavlov, ... MD , president and CEO of The Feinstein ... an analysis of how the nervous system regulates the ... develop bioelectronic medicine devices to treat disease ... Nature Neuroscience . The paper examines various ...
(Date:1/14/2017)... San Diego, CA (PRWEB) , ... January 14, ... ... availability of Proximo™, a new service providing complete end-to-end genome assemblies to researchers ... to complete genomes eliminates a major obstacle in answering a wide range of ...
(Date:1/13/2017)... Research and Markets has announced the addition of the "Global Biopolymers ... ... of 16.83% during the period 2017-2021. The report covers ... for 2017-2021. To calculate the market size, the report considers the revenue ... includes a a discussion of the key vendors operating in this market. ...
Breaking Biology Technology: